Cancer vaccines

Tim F. Greten, Elizabeth Jaffee

Research output: Contribution to journalArticle

Abstract

It has been more than 100 years since the first reported attempts to activate a patient's immune system to eradicate developing cancers. Although a few of the subsequent vaccine studies demonstrated clinically significant treatment effects, active immunotherapy has not yet become an established cancer treatment modality. Two recent advances have allowed the design of more specific cancer vaccine approaches: improved molecular biology techniques and a greater understanding of the mechanisms involved in the activation of T cells. These advances have resulted in improved systemic antitumor immune responses in animal models. Because most tumor antigens recognized by T cells are still not known, the tumor cell itself is the best source of immunizing antigens. For this reason, most vaccine approaches currently being tested in the clinics use whole cancer cells that have been genetically modified to express genes that are now known to be critical mediators of immune system activation. In the future, the molecular definition of tumor-specific antigens that are recognized by activated T cells will allow the development of targeted antigen-specific vaccines for the treatment of patients with cancer.

Original languageEnglish (US)
Pages (from-to)1047-1060
Number of pages14
JournalJournal of Clinical Oncology
Volume17
Issue number3
StatePublished - Mar 1999

Fingerprint

Cancer Vaccines
Vaccines
Neoplasm Antigens
Neoplasms
T-Lymphocytes
Immune System
Antigens
Active Immunotherapy
Molecular Biology
Therapeutics
Animal Models
Genes

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Greten, T. F., & Jaffee, E. (1999). Cancer vaccines. Journal of Clinical Oncology, 17(3), 1047-1060.

Cancer vaccines. / Greten, Tim F.; Jaffee, Elizabeth.

In: Journal of Clinical Oncology, Vol. 17, No. 3, 03.1999, p. 1047-1060.

Research output: Contribution to journalArticle

Greten, TF & Jaffee, E 1999, 'Cancer vaccines', Journal of Clinical Oncology, vol. 17, no. 3, pp. 1047-1060.
Greten TF, Jaffee E. Cancer vaccines. Journal of Clinical Oncology. 1999 Mar;17(3):1047-1060.
Greten, Tim F. ; Jaffee, Elizabeth. / Cancer vaccines. In: Journal of Clinical Oncology. 1999 ; Vol. 17, No. 3. pp. 1047-1060.
@article{2db2f933abcc4359a1f8fcf32802e79c,
title = "Cancer vaccines",
abstract = "It has been more than 100 years since the first reported attempts to activate a patient's immune system to eradicate developing cancers. Although a few of the subsequent vaccine studies demonstrated clinically significant treatment effects, active immunotherapy has not yet become an established cancer treatment modality. Two recent advances have allowed the design of more specific cancer vaccine approaches: improved molecular biology techniques and a greater understanding of the mechanisms involved in the activation of T cells. These advances have resulted in improved systemic antitumor immune responses in animal models. Because most tumor antigens recognized by T cells are still not known, the tumor cell itself is the best source of immunizing antigens. For this reason, most vaccine approaches currently being tested in the clinics use whole cancer cells that have been genetically modified to express genes that are now known to be critical mediators of immune system activation. In the future, the molecular definition of tumor-specific antigens that are recognized by activated T cells will allow the development of targeted antigen-specific vaccines for the treatment of patients with cancer.",
author = "Greten, {Tim F.} and Elizabeth Jaffee",
year = "1999",
month = "3",
language = "English (US)",
volume = "17",
pages = "1047--1060",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "3",

}

TY - JOUR

T1 - Cancer vaccines

AU - Greten, Tim F.

AU - Jaffee, Elizabeth

PY - 1999/3

Y1 - 1999/3

N2 - It has been more than 100 years since the first reported attempts to activate a patient's immune system to eradicate developing cancers. Although a few of the subsequent vaccine studies demonstrated clinically significant treatment effects, active immunotherapy has not yet become an established cancer treatment modality. Two recent advances have allowed the design of more specific cancer vaccine approaches: improved molecular biology techniques and a greater understanding of the mechanisms involved in the activation of T cells. These advances have resulted in improved systemic antitumor immune responses in animal models. Because most tumor antigens recognized by T cells are still not known, the tumor cell itself is the best source of immunizing antigens. For this reason, most vaccine approaches currently being tested in the clinics use whole cancer cells that have been genetically modified to express genes that are now known to be critical mediators of immune system activation. In the future, the molecular definition of tumor-specific antigens that are recognized by activated T cells will allow the development of targeted antigen-specific vaccines for the treatment of patients with cancer.

AB - It has been more than 100 years since the first reported attempts to activate a patient's immune system to eradicate developing cancers. Although a few of the subsequent vaccine studies demonstrated clinically significant treatment effects, active immunotherapy has not yet become an established cancer treatment modality. Two recent advances have allowed the design of more specific cancer vaccine approaches: improved molecular biology techniques and a greater understanding of the mechanisms involved in the activation of T cells. These advances have resulted in improved systemic antitumor immune responses in animal models. Because most tumor antigens recognized by T cells are still not known, the tumor cell itself is the best source of immunizing antigens. For this reason, most vaccine approaches currently being tested in the clinics use whole cancer cells that have been genetically modified to express genes that are now known to be critical mediators of immune system activation. In the future, the molecular definition of tumor-specific antigens that are recognized by activated T cells will allow the development of targeted antigen-specific vaccines for the treatment of patients with cancer.

UR - http://www.scopus.com/inward/record.url?scp=0000023712&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0000023712&partnerID=8YFLogxK

M3 - Article

C2 - 10071300

AN - SCOPUS:0000023712

VL - 17

SP - 1047

EP - 1060

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 3

ER -